Liu Y, Zhu Z, Xu Q, Xu J, Xing J, Wang S
BMC Immunol. 2025; 26(1):11.
PMID: 40022006
PMC: 11869739.
DOI: 10.1186/s12865-025-00691-x.
Hamasy A, Hussain A, Mohammad D, Wang Q, Sfetcovici M, Nore B
Sci Rep. 2025; 15(1):814.
PMID: 39755731
PMC: 11700165.
DOI: 10.1038/s41598-024-83962-8.
Sundaramoorthy S, Colombo D, Sanalkumar R, Broye L, Balmas Bourloud K, Boulay G
JCI Insight. 2024; 9(14).
PMID: 39133652
PMC: 11383371.
DOI: 10.1172/jci.insight.169647.
Thevkar Nagesh P, Cho Y, Zhuang Y, Babuta M, Ortega-Ribera M, Joshi R
Sci Transl Med. 2024; 16(759):eadg1915.
PMID: 39110779
PMC: 11831603.
DOI: 10.1126/scitranslmed.adg1915.
Himmelbauer M, Bajrami B, Basile R, Capacci A, Chen T, Choi C
J Med Chem. 2024; 67(10):8122-8140.
PMID: 38712838
PMC: 11129193.
DOI: 10.1021/acs.jmedchem.4c00220.
Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states.
Lin D, Kueffer L, Juneja P, Wales T, Engen J, Andreotti A
Elife. 2024; 12.
PMID: 38189455
PMC: 10945472.
DOI: 10.7554/eLife.89489.
Pathogenetic Dichotomy in Angioleiomyoma.
Panagopoulos I, Andersen K, Brunetti M, Gorunova L, Kostolomov I, Kildal W
Cancer Genomics Proteomics. 2023; 20(6):556-566.
PMID: 37889065
PMC: 10614064.
DOI: 10.21873/cgp.20405.
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.
Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan N
Cell Rep Med. 2023; 4(10):101199.
PMID: 37738978
PMC: 10591038.
DOI: 10.1016/j.xcrm.2023.101199.
Overexpression of Bruton Tyrosine Kinase Inhibits the Proliferation, Migration, and Invasion of Non-Small Cell Lung Cancer Cells.
Ren W, Yue C, Liu L, Du L, Xu K, Zhou Y
Anal Cell Pathol (Amst). 2023; 2023:3377316.
PMID: 37638060
PMC: 10457169.
DOI: 10.1155/2023/3377316.
Bruton tyrosine kinase inhibitors for multiple sclerosis.
Kramer J, Bar-Or A, Turner T, Wiendl H
Nat Rev Neurol. 2023; 19(5):289-304.
PMID: 37055617
PMC: 10100639.
DOI: 10.1038/s41582-023-00800-7.
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Dong R, Yan Y, Zeng X, Lin N, Tan B
Drug Des Devel Ther. 2022; 16:3225-3239.
PMID: 36164415
PMC: 9508996.
DOI: 10.2147/DDDT.S377697.
Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M
Clin Transl Sci. 2022; 15(12):2888-2898.
PMID: 36126241
PMC: 9747124.
DOI: 10.1111/cts.13407.
Exploring the Role of Chemical Reactions in the Selectivity of Tyrosine Kinase Inhibitors.
Asadi M, Xie W, Warshel A
J Am Chem Soc. 2022; 144(36):16638-16646.
PMID: 36044733
PMC: 10387326.
DOI: 10.1021/jacs.2c07307.
MicroRNA-155 acts as an anti-inflammatory factor in orbital fibroblasts from Graves' orbitopathy by repressing interleukin-2-inducible T-cell kinase.
Choi Y, Kim C, Choi E, Lee S, Chae M, Jun H
PLoS One. 2022; 17(8):e0270416.
PMID: 35980936
PMC: 9387810.
DOI: 10.1371/journal.pone.0270416.
The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.
Ye B, Chen S, Guo H, Zheng W, Lou G, Liang X
J Immunol. 2022; 209(6):1156-1164.
PMID: 35977799
PMC: 10613575.
DOI: 10.4049/jimmunol.2001323.
Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.
Zheng T, Parra-Izquierdo I, Reitsma S, Heinrich M, Larson M, Shatzel J
Am J Physiol Cell Physiol. 2022; 323(4):C1231-C1250.
PMID: 35938677
PMC: 9576167.
DOI: 10.1152/ajpcell.00040.2022.
Palmitoylation of the Alternative Amino Terminus of the BTK-C Isoform Controls Subcellular Distribution and Signaling.
Kokabee M, Wang X, Voorand E, Alin E, Kokabee L, Khan F
Cancer Genomics Proteomics. 2022; 19(4):415-427.
PMID: 35732327
PMC: 9247882.
DOI: 10.21873/cgp.20329.
Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim G, Wampole M, Oberoi K
Front Immunol. 2021; 12:662223.
PMID: 34803999
PMC: 8595937.
DOI: 10.3389/fimmu.2021.662223.
CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis.
Yang H, Liu X, Zhu X, Li X, Jiang L, Zhong M
JCI Insight. 2021; 6(24).
PMID: 34784299
PMC: 8783677.
DOI: 10.1172/jci.insight.146362.
Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection.
Byun J, Koh Y, Jang S, Witcher J, Chan J, Pustilnik A
Sci Rep. 2021; 11(1):18671.
PMID: 34548595
PMC: 8455565.
DOI: 10.1038/s41598-021-98255-7.